[pending] ALYACEN 1/35 (NORETHINDRONE AND ETHINYL ESTRADIOL)
Pending LLM rewrite. Source: FDA_DRUG D-0588-2026.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
The recalled product
- Product
- ALYACEN 1/35 (NORETHINDRONE AND ETHINYL ESTRADIOL)
- Brand
- ALYACEN 1/35
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 20240411
- Exp: 6/30/2026
- 20250252
- Exp: 3/31/2027
UPCs (3)
- 0368462394847
- 0368462394298
- 0368462556849
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAccucaine Lidocaine Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Sterile Solution Lacks Assurance of Sterility
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Applicators Recalled for Lack of Sterile Assurance
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Antiseptic Applicators recalled for lack of sterility assurance
FDA (Drugs) · 2026-07-08